Please assess the completion status of the following clinical trial:

Trial Title: Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~-Men and women aged 18 to 70 with untreated vestibular migraine variant as diagnosed by history.~Exclusion Criteria:~* Patients with allergies to nortriptyline or topiramate and their analogs or medication interactions that preclude their use.~* Patients under the care of a psychiatrist.~* Patients who are pregnant or trying to become pregnant.~* Patients taking more than 5 prescription medications.~* Patients with cancer.~* Patient has a history of immunodeficiency.~* Patient has a history of substance abuse within the preceding 6 months prior to screening.~* Patient has used an investigational drug or device in the the 3 months prior to screening.~* Patient is using marijuana for medical or other uses.~* Patient has any other clinically significant illness or medical condition that, in the investigator's opinion, would prohibit the subject from participating in the study.~* Patient with traumatic brain injury.~* Patients taking Nortriptyline, MAOIs~* Patients with liver or kidney dysfunction or glaucoma~Due to know drug interactions, patients taking the following medications will be excluded.~Nortriptyline: monoamine oxidase inhibitors (MAO) such as phenelzine. Patients on oral contraceptives will be asked to use a secondary method as nortriptyline can reduce the effectiveness of oral contraceptives.~Topiramate: acetazolamide (kidney stones), digoxin~Exclude subjects with liver dysfunction, kidney dysfunction and glaucoma (per the risks associated with topiramate).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- nortriptyline (Type: ACTIVE_COMPARATOR): If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to nortriptyline for eight (8) weeks. If still experiencing symptoms, they will receive topiramate for eight (8) weeks.
- topiramate (Type: ACTIVE_COMPARATOR): If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to topiramate for eight (8) weeks. If still experiencing symptoms, they will receive nortriptyline for eight (8) weeks.
- diet modification (Type: OTHER): Participants will begin with diet modification for four (4) weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).